Omnicell (NASDAQ:OMCL) Exceeds Q4 Expectations But Full-Year Sales Guidance Misses Expectations
Healthcare tech company Omnicell (NASDAQ:OMCL) reported Q4 CY2024 results topping the market’s revenue expectations, with sales up 18.6% year on year to $306.9 million. On the other hand, next quarter’s revenue guidance of $260 million was less impressive, coming in 2% below analysts’ estimates. Its non-GAAP profit of $0.60 per share was 2.8% above analysts’ consensus estimates.